Published in Mol Cell Biol on January 01, 1993
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol (2011) 2.96
Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol (1996) 1.93
Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer (2013) 1.80
A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein. EMBO J (1997) 1.60
The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol Cell Biol (1995) 1.38
High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res (2009) 1.29
Signaling through dynamic linkers as revealed by PKA. Proc Natl Acad Sci U S A (2013) 1.28
Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clin Cancer Res (2008) 1.27
MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther (2010) 1.08
Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain. Mol Cell Biol (1997) 0.98
Shc and Enigma are both required for mitogenic signaling by Ret/ptc2. Mol Cell Biol (1998) 0.96
A new mechanism of BRAF activation in human thyroid papillary carcinomas. J Clin Invest (2005) 0.93
The neuronal scaffold protein Shank3 mediates signaling and biological function of the receptor tyrosine kinase Ret in epithelial cells. J Cell Biol (2004) 0.92
Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism. Mol Cell Biol (1998) 0.92
Specific haplotypes of the RET proto-oncogene are over-represented in patients with sporadic papillary thyroid carcinoma. J Med Genet (2002) 0.91
Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours. Br J Cancer (1993) 0.91
Thyroid cancer: current molecular perspectives. J Oncol (2010) 0.87
Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements. Br J Cancer (2001) 0.85
Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma. Front Endocrinol (Lausanne) (2012) 0.83
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev Endocrinol (2016) 0.83
BAC-FISH assays delineate complex chromosomal rearrangements in a case of post-Chernobyl childhood thyroid cancer. Folia Histochem Cytobiol (2009) 0.82
Additive antisense effects of different PNAs on the in vitro translation of the PML/RARalpha gene. Nucleic Acids Res (1998) 0.82
Central role of RET in thyroid cancer. Cold Spring Harb Perspect Biol (2013) 0.79
RET activation in adult and childhood papillary thyroid carcinoma using a reverse transcriptase-n-polymerase chain reaction approach on archival-nested material. Br J Cancer (1996) 0.79
Expression of Ret/PTC1, -2, -3, -delta3 and -4 in German papillary thyroid carcinoma. Br J Cancer (1998) 0.78
Sympathoadrenal hyperplasia causes renal malformations in Ret(MEN2B)-transgenic mice. Am J Pathol (1999) 0.77
Delineating chromosomal breakpoints in radiation-induced papillary thyroid cancer. Genes (Basel) (2011) 0.77
The RET proto-oncogene: a challenge to our understanding of disease pathogenesis. Pediatr Surg Int (1997) 0.75
RET proto-oncogene mutations and rearrangements in endocrine diseases. Am J Pathol (1995) 0.75
Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma. Oncotarget (2016) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A (1979) 365.71
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem (1983) 206.01
A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature (1986) 5.88
cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. Annu Rev Biochem (1990) 5.02
PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell (1990) 3.98
Phosphotyrosine-containing proteins isolated by affinity chromatography with antibodies to a synthetic hapten. Nature (1981) 2.08
Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene (1988) 1.95
High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene (1989) 1.94
The cyclic AMP-mediated stimulation of cell proliferation. Trends Biochem Sci (1989) 1.64
Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy. Cancer Res (1990) 1.60
The tissue-specific extinguisher locus TSE1 encodes a regulatory subunit of cAMP-dependent protein kinase. Cell (1991) 1.59
TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene (1992) 1.55
Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Natl Acad Sci U S A (1992) 1.46
Detection and purification of inhibin using antisera generated against synthetic peptide fragments. Methods Enzymol (1989) 1.38
Subtractive hybridization cloning of a tissue-specific extinguisher: TSE1 encodes a regulatory subunit of protein kinase A. Cell (1991) 1.28
Characterization of ret proto-oncogene mRNAs encoding two isoforms of the protein product in a human neuroblastoma cell line. Oncogene (1990) 1.21
Alkaline phosphatase: affinity chromatography and inhibition by phosphonic acids. Biochemistry (1978) 1.09
Receptor for bombesin with associated tyrosine kinase activity. Mol Cell Biol (1986) 1.08
Identification of a high affinity binding protein for the regulatory subunit RII beta of cAMP-dependent protein kinase in Golgi enriched membranes of human lymphoblasts. EMBO J (1992) 1.03
Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas. Oncogene (1992) 0.96
Interchain disulfide bonding in the regulatory subunit of cAMP-dependent protein kinase I. J Biol Chem (1982) 0.92
The two mRNA forms for the type I alpha regulatory subunit of cAMP-dependent protein kinase from human testis are due to the use of different polyadenylation site signals. Biochem Biophys Res Commun (1990) 0.92
Expression of the ETS2 and transferrin receptor genes in Philadelphia-positive chronic myeloid leukemia patients with a reciprocal t(3;21). Genes Chromosomes Cancer (1992) 0.91
PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell (1990) 3.98
Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science (1984) 2.97
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol (2008) 2.75
A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature (1987) 2.60
The FHIT gene 3p14.2 is abnormal in lung cancer. Cell (1996) 2.36
Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci U S A (1997) 2.36
Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol (1999) 2.11
A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J Biol Chem (1998) 1.98
Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res (1998) 1.96
High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene (1989) 1.94
Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene (1994) 1.87
Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res (1996) 1.85
Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res (2001) 1.76
bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood (1992) 1.69
A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res (1996) 1.60
Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer (1991) 1.58
Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest (1993) 1.57
TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene (1992) 1.55
p53 activity and chemotherapy. Nat Med (1996) 1.53
Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest (1992) 1.52
Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene (1992) 1.51
Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res (1992) 1.50
The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci U S A (1999) 1.47
Structural features and selective expression of three Ly-5+ cell-surface molecules. Immunogenetics (1981) 1.47
Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Natl Acad Sci U S A (1992) 1.46
CD34 expression is regulated reciprocally with adhesion molecules in vascular endothelial cells in vitro. Blood (1993) 1.44
Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res (1997) 1.39
The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol Cell Biol (1995) 1.38
Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res (1995) 1.33
Loss of function effect of RET mutations causing Hirschsprung disease. Nat Genet (1995) 1.33
A novel zinc finger gene is fused to EWS in small round cell tumor. Oncogene (2000) 1.33
Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol Cell Endocrinol (2009) 1.33
Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcoma. Lab Invest (2000) 1.30
Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene (2007) 1.28
Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest (2001) 1.26
Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer (2001) 1.26
Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res (1994) 1.22
Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol (1994) 1.20
Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online. Hum Mutat (1998) 1.19
Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res (1997) 1.18
A major susceptibility locus to murine lung carcinogenesis maps on chromosome 6. Nat Genet (1993) 1.18
Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms. J Pathol (1997) 1.18
Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene (2006) 1.17
Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22. J Pathol (1998) 1.15
Bmx tyrosine kinase has a redundant function downstream of angiopoietin and vascular endothelial growth factor receptors in arterial endothelium. Mol Cell Biol (2001) 1.15
p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol (2000) 1.14
A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. Genomics (1995) 1.14
The oncogenic versions of the Ret and Trk tyrosine kinases bind Shc and Grb2 adaptor proteins. Oncogene (1994) 1.14
Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett (2008) 1.11
Mapping of body weight loci on mouse chromosome X. Mamm Genome (1995) 1.10
The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Mol Cell Biol (1996) 1.09
PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma. J Pathol (2006) 1.08
Human glial cell line-derived neurotrophic factor receptor alpha 4 is the receptor for persephin and is predominantly expressed in normal and malignant thyroid medullary cells. J Biol Chem (2000) 1.08
Refined localization to contiguous regions on chromosome 10q of the two genes (H4 and RET) that form the oncogenic sequence PTC. Oncogene (1991) 1.07
RET activation by germline MEN2A and MEN2B mutations. Oncogene (1995) 1.07
4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem (1996) 1.07
The oncogene associated with human papillary thyroid carcinoma (PTC) is assigned to chromosome 10 q11-q12 in the same region as multiple endocrine neoplasia type 2A (MEN2A). Oncogene (1989) 1.07
Aberrant FHIT transcripts in Merkel cell carcinoma. Cancer Res (1996) 1.06
Ring 22 chromosomes in dermatofibrosarcoma protuberans are low-level amplifiers of chromosome 17 and 22 sequences. Cancer Res (1995) 1.06
Induction of TNF-sensitive cellular phenotype by c-Myc involves p53 and impaired NF-kappaB activation. EMBO J (1997) 1.05
11q deletions in human colorectal carcinomas: cytogenetics and restriction fragment length polymorphism analysis. Genes Chromosomes Cancer (1993) 1.05
Cytogenetic abnormalities and overexpression of receptors for growth factors in normal bronchial epithelium and tumor samples of lung cancer patients. Cancer Res (1991) 1.05
In vitro demonstration of tumor-specific common antigens and embryonal antigens in murine fibrosarcomas induced by 7,12-dimethylbenz(a)anthracene. Cancer Res (1973) 1.05
Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur J Cancer (1994) 1.05
RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res (1998) 1.05
IGFBP7: an oncosuppressor gene in thyroid carcinogenesis. Oncogene (2010) 1.05
Expression of retroviral sequences and oncogenes in murine hepatocellular tumors. Cancer Res (1986) 1.05
Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res (1999) 1.04
Identification of Shc docking site on Ret tyrosine kinase. Oncogene (1997) 1.04
Chromosome mapping of murine susceptibility loci to liver carcinogenesis. Cancer Res (1993) 1.03
Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations. Oncogene (1997) 1.03
Genetic mapping of lung cancer modifier loci specifically affecting tumor initiation and progression. Cancer Res (1997) 1.03